【4588】オンコリスバイオファーマ
製薬。がん治療薬。
売上高
営業利益
経常利益
当期利益
業績予想修正
対前回修正率
当初予想比較
決算期 | 日付 | 予・実 | 売上高 (百万円) | 対前回 | 営業利益 (百万円) | 対前回 | 経常利益 (百万円) | 対前回 | 当期利益 (百万円) | 対前回 |
---|---|---|---|---|---|---|---|---|---|---|
2023.12 | 2024/02/09 | 実 | 63 | → | -1,929 | ↓ | -1,913 | ↓ | -1,938 | ↓ |
2023.12 | 2023/12/15 | 当初予 | 63 | - | -1,806 | - | -1,775 | - | -1,777 | - |
2022.12 | 2023/02/10 | 実 | 976 | ↓ | -1,204 | ↑ | -1,163 | ↑ | -1,148 | ↑ |
2022.12 | 2022/11/04 | Q3予 | 1,000 | → | -1,600 | → | -1,600 | → | -1,600 | → |
2022.12 | 2022/08/05 | Q2予 | 1,000 | → | -1,600 | → | -1,600 | → | -1,600 | → |
2022.12 | 2022/05/13 | Q1予 | 1,000 | → | -1,600 | → | -1,600 | → | -1,600 | → |
2022.12 | 2022/02/10 | 当初予 | 1,000 | - | -1,600 | - | -1,600 | - | -1,600 | - |
2021.12 | 2022/02/10 | 実 | 642 | → | -1,454 | ↓ | -1,500 | ↓ | -1,615 | ↓ |
2021.12 | 2022/01/24 | 修正予 | 642 | ↑ | -1,421 | ↑ | -1,468 | ↑ | -1,582 | ↑ |
2021.12 | 2021/11/05 | Q3予 | 525 | → | -1,825 | → | -1,825 | → | -1,825 | → |
2021.12 | 2021/08/06 | Q2予 | 525 | → | -1,825 | → | -1,825 | → | -1,825 | → |
2021.12 | 2021/05/07 | Q1予 | 525 | → | -1,825 | → | -1,825 | → | -1,825 | → |
2021.12 | 2021/02/12 | 当初予 | 525 | - | -1,825 | - | -1,825 | - | -1,825 | - |
2020.12 | 2021/02/12 | 実 | 314 | - | -1,674 | - | -1,723 | - | -2,095 | - |
2019.12 | 2020/02/07 | 実 | 1,303 | - | -511 | - | -539 | - | -912 | - |
2018.12 | 2019/02/08 | 実 | 168 | ↑ | -1,247 | ↑ | -1,230 | ↑ | -1,233 | ↑ |
2018.12 | 2019/01/18 | 修正予 | 160 | ↓ | -1,250 | ↑ | -1,250 | ↑ | -1,250 | ↑ |
2018.12 | 2018/11/02 | Q3予 | 230 | → | -1,400 | → | -1,400 | → | -1,400 | → |
2018.12 | 2018/08/03 | Q2予 | 230 | → | -1,400 | → | -1,400 | → | -1,400 | → |
2018.12 | 2018/05/02 | Q1予 | 230 | → | - | - | -1,400 | → | -1,400 | → |
2018.12 | 2018/02/09 | 当初予 | 230 | - | -1,400 | - | -1,400 | - | -1,400 | - |
2017.12 | 2018/02/09 | 実 | 229 | → | -1,078 | ↑ | -1,087 | → | -1,090 | → |
2017.12 | 2018/01/31 | 修正予 | 229 | ↑ | - | - | -1,087 | ↑ | -1,090 | ↑ |
2017.12 | 2017/11/02 | Q3予 | 200 | → | -1,400 | → | -1,400 | → | -1,400 | → |
2017.12 | 2017/08/04 | Q2予 | 200 | → | -1,400 | → | -1,400 | → | -1,400 | → |
2017.12 | 2017/05/02 | Q1予 | 200 | → | -1,400 | → | -1,400 | → | -1,400 | → |
2017.12 | 2017/02/08 | 当初予 | 200 | - | -1,400 | - | -1,400 | - | -1,400 | - |
2016.12 | 2017/02/08 | 実 | 178 | ↓ | -861 | ↑ | -864 | ↑ | -931 | ↑ |
2016.12 | 2016/08/04 | Q2予 | 188 | → | -1,273 | → | -1,273 | → | -1,276 | → |
2016.12 | 2016/04/28 | Q1予 | 188 | → | -1,273 | → | -1,273 | → | -1,276 | → |
2016.12 | 2016/02/10 | 当初予 | 188 | - | -1,273 | - | -1,273 | - | -1,276 | - |
2015.12 | 2016/02/10 | 実 | 121 | ↑ | -951 | ↑ | -854 | ↑ | -857 | ↑ |
2015.12 | 2015/11/24 | 修正予 | 118 | ↑ | -1,064 | ↑ | -1,064 | ↑ | -968 | ↑ |
2015.12 | 2015/11/12 | Q3予 | 105 | → | -1,602 | → | -1,509 | → | -1,512 | → |
2015.12 | 2015/08/12 | Q2予 | 105 | → | -1,602 | → | -1,509 | → | -1,512 | → |
2015.12 | 2015/05/13 | Q1予 | 105 | → | -1,602 | → | -1,509 | → | -1,512 | → |
2015.12 | 2015/02/12 | 当初予 | 105 | - | -1,602 | - | -1,509 | - | -1,512 | - |
2014.12 | 2015/02/12 | 実 | 28 | → | -827 | ↑ | -726 | ↑ | -738 | ↓ |
2014.12 | 2015/01/23 | 修正予 | 28 | ↓ | -830 | ↓ | -830 | ↓ | -736 | ↓ |
2014.12 | 2014/11/12 | Q3予 | 544 | → | -734 | → | -618 | → | -620 | → |
2014.12 | 2014/08/12 | Q2予 | 544 | → | -734 | → | -618 | → | -620 | → |
2014.12 | 2014/05/13 | Q1予 | 544 | → | -734 | → | -618 | → | -620 | → |
2014.12 | 2014/04/14 | 修正予 | 544 | ↓ | -734 | ↓ | -618 | ↓ | -620 | ↓ |
2014.12 | 2014/02/14 | 当初予 | 1,164 | - | -102 | - | 24 | - | 21 | - |
2013.12 | 2014/02/14 | 実 | 1 | - | -665 | - | -625 | - | -635 | - |